Genes of drug-resistant tb in central africa
Part of Infections, Injuries & trauma clinical trials.
This study looks at the genes of tuberculosis (TB) bacteria in Central Africa to understand drug-resistant strains. If you have TB, your sample may help researchers learn more about how to treat it better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 8 years old.
- You must have a positive GeneXpert test, meaning a quick test shows you have TB.
- You must be able to give a sputum sample (phlegm) for testing.
- You must agree to let researchers use your sample and health data for this study.
- If you are already in another TB study, you may join without signing a new consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment plan for people who have both drug-resistant tuberculosis (TB) and HIV. It focuses on starting a specific TB medication (bedaquiline) and, if needed, HIV treatment soon after enrollment to see what approach works best.
This study looks at how tuberculosis bacteria become resistant to drugs. If you have tested positive for TB, this study might help find better treatments for resistant TB.
This study looks at whether TB bacteria are resistant to the drugs used for treatment. It helps doctors understand which medicines work best for newly diagnosed patients.
This study uses next-generation gene testing to help manage active drug-resistant tuberculosis. It may help doctors choose the most appropriate treatment by better identifying the TB’s drug resistance.
This study tests whether using a detailed sputum test to guide treatment for drug-resistant tuberculosis (TB) leads to better outcomes. Participants' treatment is tailored based on the specific drug resistance found, which may help them recover faster and reduce side effects.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
Hear when a new Strains trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.